Dyax and Aveo sign antibody licensing agreement

Dyax’s human antibody phage libraries combine gene fragments from human donors with strategically designed synthetic DNA, and are used to identify high-affinity human antibodies that bind to numerous therapeutic targets, including cell surface proteins such as tumor cell markers, viral antigens, enzymes, and glycoproteins.

The terms of this strategic agreement include upfront and annual license fees, clinical and regulatory milestone payments as well as other considerations. Dyax is also entitled to royalties on net sales of any products identified by Aveo using Dyax’s technology that may be developed and commercialized by Aveo and/or its sublicenses.

The agreement also provides Aveo with sublicenses to relevant third-party antibody phage display patents related to Dyax’s technology.

Henry Blair, chairman, president and CEO of Dyax, said: “The innovative structure of this agreement is another example of our strategy to expand our licensed antibody pipeline through a wide variety of strategic partnerships and collaborations.”